title: Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
abstract: Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: G
authors.initials: G
authors.lastname: Varuni Kondagunta
authors.forename: Jennifer
authors.initials: J
authors.lastname: Bacik
authors.forename: Lawrence
authors.initials: L
authors.lastname: Schwartz
authors.forename: Joel
authors.initials: J
authors.lastname: Sheinfeld
authors.forename: Dean
authors.initials: D
authors.lastname: Bajorin
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Vuky
authors.forename: Stephanie
authors.initials: S
authors.lastname: Marion
authors.forename: Madhu
authors.initials: M
authors.lastname: Mazumdar
authors.forename: George J
authors.initials: GJ
authors.lastname: Bosl
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer
mesh_terms: D000328:Adult; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D016001:Confidence Intervals; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000502:physiology; D005260:Female; D018237:Germinoma / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008479:Mediastinal Neoplasms / Q000097:blood / Q000188:drug therapy; D000077204:Temozolomide; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy
chemical_list: D003606:Dacarbazine; D002945:Cisplatin; D000077204:Temozolomide